AU2021255809B2 - Bi- and monocyclic nucleoside analogs for treatment of hepatitis E - Google Patents
Bi- and monocyclic nucleoside analogs for treatment of hepatitis EInfo
- Publication number
- AU2021255809B2 AU2021255809B2 AU2021255809A AU2021255809A AU2021255809B2 AU 2021255809 B2 AU2021255809 B2 AU 2021255809B2 AU 2021255809 A AU2021255809 A AU 2021255809A AU 2021255809 A AU2021255809 A AU 2021255809A AU 2021255809 B2 AU2021255809 B2 AU 2021255809B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- group
- pharmaceutically acceptable
- compounds
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20169480 | 2020-04-14 | ||
| EP20169480.9 | 2020-04-14 | ||
| PCT/EP2021/059504 WO2021209419A1 (en) | 2020-04-14 | 2021-04-13 | Bi- and monocyclic nucleoside analogs for treatment of hepatitis e |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021255809A1 AU2021255809A1 (en) | 2022-12-15 |
| AU2021255809B2 true AU2021255809B2 (en) | 2026-08-06 |
Family
ID=70289599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021255809A Active AU2021255809B2 (en) | 2020-04-14 | 2021-04-13 | Bi- and monocyclic nucleoside analogs for treatment of hepatitis E |
Country Status (15)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024086592A2 (en) * | 2022-10-17 | 2024-04-25 | Emory Unversity | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2025014360A1 (en) * | 2023-07-07 | 2025-01-16 | Erasmus University Medical Center Rotterdam | Guanosine nucleotide analogs for use in preventing and/or treating hepatitis e virus infection |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150366888A1 (en) * | 2014-06-24 | 2015-12-24 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2952714T3 (es) * | 2013-06-26 | 2023-11-03 | Janssen Pharmaceuticals Inc | Nucleósidos sustituidos, nucleótidos y análogos de los mismos |
| SG11201610597QA (en) * | 2014-06-24 | 2017-01-27 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| WO2017210438A1 (en) * | 2016-06-03 | 2017-12-07 | Gilead Pharmasset Llc | Methods of treating hepatitis e viral infection |
-
2021
- 2021-04-13 KR KR1020227039015A patent/KR20230002592A/ko active Pending
- 2021-04-13 PE PE2022002242A patent/PE20230386A1/es unknown
- 2021-04-13 WO PCT/EP2021/059504 patent/WO2021209419A1/en not_active Ceased
- 2021-04-13 CN CN202180028212.9A patent/CN115515603A/zh active Pending
- 2021-04-13 AU AU2021255809A patent/AU2021255809B2/en active Active
- 2021-04-13 EP EP21716786.5A patent/EP4135715B1/en active Active
- 2021-04-13 CA CA3174790A patent/CA3174790A1/en active Pending
- 2021-04-13 JP JP2022562424A patent/JP2023522615A/ja active Pending
- 2021-04-13 AR ARP210100979A patent/AR121836A1/es unknown
- 2021-04-13 PH PH1/2022/552679A patent/PH12022552679A1/en unknown
- 2021-04-13 UY UY0001039172A patent/UY39172A/es unknown
- 2021-04-13 ES ES21716786T patent/ES2982564T3/es active Active
- 2021-04-13 MX MX2022012904A patent/MX2022012904A/es unknown
- 2021-04-13 BR BR112022020825A patent/BR112022020825A2/pt unknown
-
2022
- 2022-10-12 CL CL2022002804A patent/CL2022002804A1/es unknown
-
2026
- 2026-03-11 JP JP2026038584A patent/JP2026120528A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150366888A1 (en) * | 2014-06-24 | 2015-12-24 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3174790A1 (en) | 2021-10-21 |
| US20230310481A1 (en) | 2023-10-05 |
| EP4135715A1 (en) | 2023-02-22 |
| CL2022002804A1 (es) | 2023-03-31 |
| CN115515603A (zh) | 2022-12-23 |
| PH12022552679A1 (en) | 2024-04-22 |
| BR112022020825A2 (pt) | 2022-11-29 |
| EP4135715B1 (en) | 2024-05-08 |
| ES2982564T3 (es) | 2024-10-16 |
| MX2022012904A (es) | 2023-01-24 |
| AU2021255809A1 (en) | 2022-12-15 |
| PE20230386A1 (es) | 2023-03-06 |
| UY39172A (es) | 2021-10-29 |
| EP4135715C0 (en) | 2024-05-08 |
| WO2021209419A1 (en) | 2021-10-21 |
| AR121836A1 (es) | 2022-07-13 |
| KR20230002592A (ko) | 2023-01-05 |
| JP2023522615A (ja) | 2023-05-31 |
| JP2026120528A (ja) | 2026-07-22 |